Puma Biotechnology Inc [PBYI] stock prices are up 3.55% to $5.83 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PBYI shares have gain 10.42% over the last week, with a monthly amount glided 8.97%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 3, April 2024, Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee.
From an analyst’s perspective:
Puma Biotechnology Inc [NASDAQ: PBYI] stock has seen the most recent analyst activity on September 28, 2021, when Citigroup upgraded its rating to a Buy but kept the price target unchanged to $11 for it. On October 08, 2019, downgrade downgraded it’s rating to Sell and revised its price target to $8 on the stock. Citigroup downgraded its rating to a Neutral but stick to its price target of $24 on May 10, 2019. Cantor Fitzgerald downgraded its rating to a Neutral and reduced its price target to $20 on May 10, 2019. Leerink Partners started tracking with a Mkt Perform rating for this stock on January 17, 2019, and assigned it a price target of $21. In a note dated January 03, 2019, Guggenheim downgraded an Neutral rating on this stock.
The stock price of Puma Biotechnology Inc [PBYI] has been fluctuating between $2.13 and $7.73 over the past year. Puma Biotechnology Inc [NASDAQ: PBYI] shares were valued at $5.83 at the most recent close of the market.
Analyzing the PBYI fundamentals
The Puma Biotechnology Inc [NASDAQ:PBYI] reported sales of 235.64M for trailing twelve months, representing a surge of 9.90%. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.1%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.58 and Total Capital is 0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.60 points at the first support level, and at 5.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.06, and for the 2nd resistance point, it is at 6.29.
Puma Biotechnology Inc [PBYI] reported earnings per share of $0.26 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.3/share, meaning a difference of -$0.04 and a surprise factor of -13.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.12 per share as compared to estimates of $0.08 per share, a difference of $0.04 representing a surprise of 50.00%.
Ratios To Look Out For
It’s worth pointing out that Puma Biotechnology Inc [NASDAQ:PBYI]’s Current Ratio is 1.57. As well, the Quick Ratio is 1.50, while the Cash Ratio is 0.85. Considering the valuation of this stock, the price to sales ratio is 1.19, the price to book ratio is 5.20 and price to earnings (TTM) ratio is 12.92.
Transactions by insiders
Recent insider trading involved AUERBACH ALAN H, President and CEO, that happened on Jan 03 ’24 when 41396.0 shares were sold. Chief Financial Officer, NOUGUES MAXIMO F completed a deal on Jan 03 ’24 to sell 15682.0 shares. Meanwhile, Chief Commercial Officer Ludwig Jeffrey Jerome sold 12956.0 shares on Jan 03 ’24.
